News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
574,043 Results
Type
Article (30809)
Company Profile (180)
Press Release (543054)
Section
Business (167679)
Career Advice (1588)
Deals (29901)
Drug Delivery (89)
Drug Development (70382)
Employer Resources (83)
FDA (14389)
Job Trends (12487)
News (285257)
Policy (24260)
Tag
Academia (2209)
Alliances (43374)
Alzheimer's disease (1059)
Approvals (14362)
Artificial intelligence (181)
Bankruptcy (242)
Best Places to Work (10257)
Biotechnology (126)
Breast cancer (199)
Cancer (1471)
Cardiovascular disease (117)
Career advice (1280)
CAR-T (100)
Cell therapy (298)
Clinical research (56895)
Collaboration (559)
Compensation (253)
COVID-19 (2180)
C-suite (119)
Data (1408)
Diabetes (199)
Diagnostics (6006)
Earnings (70053)
Events (87200)
Executive appointments (406)
FDA (15107)
Funding (476)
Gene therapy (197)
GLP-1 (714)
Government (3211)
Healthcare (16089)
Infectious disease (2272)
Inflammatory bowel disease (108)
Interviews (275)
IPO (14657)
Job creations (2673)
Job search strategy (1114)
Layoffs (328)
Legal (5079)
Lung cancer (215)
Manufacturing (213)
Medical device (13005)
Medtech (13010)
Mergers & acquisitions (15552)
Metabolic disorders (536)
Neuroscience (1380)
NextGen: Class of 2025 (5425)
Non-profit (3422)
Northern California (1679)
Obesity (305)
Opinion (153)
Patents (109)
People (43809)
Phase I (19190)
Phase II (24548)
Phase III (18280)
Pipeline (595)
Postmarket research (1924)
Preclinical (7062)
Radiopharmaceuticals (230)
Rare diseases (252)
Real estate (4653)
Regulatory (17294)
Research institute (2054)
Resumes & cover letters (288)
Southern California (1484)
Startups (3097)
United States (14869)
Vaccines (510)
Weight loss (233)
Date
Today (186)
Last 7 days (877)
Last 30 days (2044)
Last 365 days (32615)
2025 (1252)
2024 (32750)
2023 (36637)
2022 (47005)
2021 (50359)
2020 (47723)
2019 (40116)
2018 (30455)
2017 (29164)
2016 (27013)
2015 (31609)
2014 (23645)
2013 (19419)
2012 (20743)
2011 (21307)
2010 (19449)
Location
Africa (612)
Arizona (144)
Asia (35626)
Australia (5934)
California (3789)
Canada (1399)
China (351)
Colorado (176)
Connecticut (184)
Europe (78508)
Florida (527)
Georgia (127)
Illinois (366)
Indiana (220)
Japan (99)
Maryland (606)
Massachusetts (2948)
Michigan (189)
Minnesota (293)
New Jersey (1088)
New York (1051)
North Carolina (751)
Northern California (1679)
Ohio (128)
Pennsylvania (857)
South America (931)
Southern California (1484)
Texas (550)
Utah (108)
Washington State (378)
574,043 Results for "medisafe 1 technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 23, 2024
·
5 min read
Genetown
Novel Randomized Control Trial Reveals Impact of Medisafe on Medication Self-Efficacy and Medication Adherence to Improve Health Outcomes in Medically Underserved Populations
A novel randomized control trial conducted by Vanderbilt University researchers and published in the Journal of Behavioral Medicine explored the effect of smartphone applications on medication adherence in a medically underserved population.
February 13, 2024
·
3 min read
Press Releases
The Colossal Foundation Donates $1.5M to the Wyss Institute at Harvard University to Advance Artificial Womb Technology for Wildlife Conservation
January 13, 2025
·
5 min read
GLP-1
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.
November 4, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B
In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.
January 8, 2025
·
3 min read
·
Tristan Manalac
Drug Development
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
Lyell Immunopharma, Inc. today announced initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology.
June 26, 2024
·
13 min read
Press Releases
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
September 24, 2024
·
2 min read
BioMidwest
Curiteva Surpasses 1,000 Procedures With Inspire(R) Cervical Trabecular PEEK(TM) With HAFUSE(R) Technology
Curiteva, Inc., a privately held manufacturing and technology company, announces over 1,000 patients have been treated with the novel 3D printed Inspire Cervical Trabecular PEEK Interbody Fusion System, resulting in over 2,000 Inspire implants placed in patients.
June 4, 2024
·
2 min read
Diabetes
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has sharply increased, according to researchers, who warn about the risk of serious side effects such as ketoacidosis.
October 24, 2024
·
2 min read
·
Tristan Manalac
Opinion
Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?
Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.
January 3, 2025
·
6 min read
·
Gary Stibel
1 of 57,405
Next
